|
BRPI0622054B8
(pt)
|
2006-09-22 |
2021-05-25 |
Oxford Amherst Llc |
composto e composição farmacêutica
|
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
US20090301928A1
(en)
*
|
2008-06-05 |
2009-12-10 |
United Comb & Novelty Corporation |
Packaging For Lipped Containers
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
TWI546290B
(zh)
|
2008-06-27 |
2016-08-21 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
ES2660418T3
(es)
|
2008-07-16 |
2018-03-22 |
Pharmacyclics Llc |
Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Ｅｇｆｒ 억제제 및 질환 치료방법
|
|
US7718662B1
(en)
*
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
CN107898791A
(zh)
|
2010-06-03 |
2018-04-13 |
药品循环有限责任公司 |
布鲁顿酪氨酸激酶(btk)抑制剂的应用
|
|
WO2012003544A1
(en)
*
|
2010-07-09 |
2012-01-12 |
The Walter And Eliza Hall Institute Of Medical Research |
Protein kinase inhibitors and methods of treatment
|
|
CN105566229A
(zh)
|
2010-08-10 |
2016-05-11 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐及其用途和制备方法
|
|
EP2635285B1
(en)
|
2010-11-01 |
2017-05-03 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
MX382354B
(es)
|
2010-11-01 |
2025-03-13 |
Celgene Car Llc |
Compuestos heterocíclicos y usos de los mismos.
|
|
JP5957003B2
(ja)
|
2010-11-10 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
変異体選択的ｅｇｆｒ阻害剤およびその使用
|
|
EP2694486B1
(en)
|
2011-04-01 |
2018-01-10 |
University of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
BR112013025387B1
(pt)
|
2011-04-01 |
2021-07-27 |
University Of Utah Research Foundation |
Compostos análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl, uso dos ditos compostos para o tratamento de um distúrbio de proliferação celular descontrolada, bem como kit compreendendo ditos compostos
|
|
CA2836449C
(en)
|
2011-05-17 |
2021-04-27 |
The Regents Of The University Of California |
Kinase inhibitors
|
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
EA025496B1
(ru)
*
|
2011-05-17 |
2016-12-30 |
Принсипиа Биофарма Инк. |
Ингибиторы тирозинкиназы
|
|
CA2840413A1
(en)
*
|
2011-06-28 |
2013-01-03 |
Pharmacyclics, Inc. |
Methods and compositions for inhibition of bone resorption
|
|
US9138436B2
(en)
|
2011-07-13 |
2015-09-22 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
AR088570A1
(es)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
TW201336847A
(zh)
*
|
2012-02-07 |
2013-09-16 |
Taiho Pharmaceutical Co Ltd |
喹啉基吡咯并嘧啶化合物或其鹽
|
|
MX351863B
(es)
*
|
2012-02-23 |
2017-10-30 |
Taiho Pharmaceutical Co Ltd |
Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
|
|
KR102081042B1
(ko)
|
2012-03-15 |
2020-02-26 |
셀젠 카르 엘엘씨 |
상피 성장 인자 수용체 키나제 억제제의 고체 형태
|
|
PL2825042T3
(pl)
|
2012-03-15 |
2019-02-28 |
Celgene Car Llc |
Sole inhibitora kinazy receptora czynnika wzrostu naskórka
|
|
ES2681050T3
(es)
|
2012-04-11 |
2018-09-11 |
Acerta Pharma B.V. |
Inhibidores de la tirosina quinasa de Bruton para la movilización hematopoyética
|
|
AU2013250726B2
(en)
|
2012-04-20 |
2017-01-05 |
Advinus Therapeutics Limited |
Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
|
|
WO2013157021A1
(en)
|
2012-04-20 |
2013-10-24 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
KR20190043648A
(ko)
*
|
2012-05-31 |
2019-04-26 |
파마사이언스 인크. |
단백질 키나제 저해제
|
|
JO3754B1
(ar)
|
2012-06-04 |
2021-01-31 |
Pharmacyclics Llc |
أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
|
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
|
ME03455B
(me)
|
2012-09-10 |
2020-01-20 |
Principia Biopharma Inc |
Jedinjenja pirazolopirimidina kao inhibitori kinaze
|
|
US9296703B2
(en)
|
2012-10-04 |
2016-03-29 |
University Of Utah Research Foundation |
Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
|
|
WO2014055928A2
(en)
|
2012-10-04 |
2014-04-10 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
EA201590855A1
(ru)
|
2012-11-15 |
2015-11-30 |
Фармасайкликс, Инк. |
Соединения пирролопиримидина как ингибиторы киназ
|
|
CN103848810A
(zh)
|
2012-11-30 |
2014-06-11 |
北京赛林泰医药技术有限公司 |
鲁顿酪氨酸激酶抑制剂
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
AU2014214846A1
(en)
|
2013-02-08 |
2015-07-23 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
|
EP2960241A4
(en)
*
|
2013-02-22 |
2016-07-13 |
Taiho Pharmaceutical Co Ltd |
PROCESS FOR PREPARING TRICYCLIC COMPOUNDS AND TRICYCLIC COMPOUNDS MADE ACCORDING TO THE SAID MANUFACTURING METHOD
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
EA201591685A1
(ru)
*
|
2013-03-15 |
2016-01-29 |
Янссен Фармацевтика Нв |
Способы и промежуточные соединения для получения лекарственного препарата
|
|
WO2014152114A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as btk inhibitors
|
|
EP2983674A4
(en)
|
2013-04-08 |
2017-05-10 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
HRP20170217T1
(hr)
|
2013-04-25 |
2017-04-21 |
Beigene, Ltd. |
Fuzinirani heterociklički spojevi kao inhibitori protein kinaze
|
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
|
CN105764501A
(zh)
|
2013-07-26 |
2016-07-13 |
现代化制药公司 |
改善比生群治疗效益的组合物
|
|
CA2919996A1
(en)
|
2013-08-02 |
2015-02-05 |
Pharmacyclics Llc |
Methods for the treatment of solid tumors
|
|
US9415050B2
(en)
|
2013-08-12 |
2016-08-16 |
Pharmacyclics Llc |
Methods for the treatment of HER2 amplified cancer
|
|
EP3037424B1
(en)
*
|
2013-08-22 |
2017-11-08 |
Taiho Pharmaceutical Co., Ltd. |
Novel quinoline-substituted compound
|
|
AU2014308616B2
(en)
|
2013-08-23 |
2018-12-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
CA2925124A1
(en)
|
2013-09-30 |
2015-04-02 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
WO2015057992A1
(en)
|
2013-10-16 |
2015-04-23 |
Izumi Raquel |
Btk inhibitors for hematopoietic mobilization
|
|
BR112016013540B1
(pt)
*
|
2013-12-13 |
2021-03-02 |
F. Hoffmann-La Roche Ag |
inibidores de tirosina quinase de bruton
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
MX2016009403A
(es)
*
|
2014-02-03 |
2016-09-16 |
Cadila Healthcare Ltd |
Compuestos heterociclicos.
|
|
PT3107544T
(pt)
|
2014-02-21 |
2021-01-05 |
Principia Biopharma Inc |
Sais e forma sólida de um inibidor de btk
|
|
WO2015143400A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics, Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
|
US9937171B2
(en)
|
2014-04-11 |
2018-04-10 |
Acerta Pharma B.V. |
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
|
CN105017256A
(zh)
*
|
2014-04-29 |
2015-11-04 |
浙江导明医药科技有限公司 |
多氟化合物作为布鲁顿酪氨酸激酶抑制剂
|
|
CN106458919B
(zh)
*
|
2014-05-13 |
2019-03-15 |
广东东阳光药业有限公司 |
一种中间体的制备方法
|
|
CN104086551B
(zh)
*
|
2014-06-06 |
2016-09-21 |
人福医药集团股份公司 |
化合物及其制备方法和用途
|
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
AU2015296215A1
(en)
|
2014-08-01 |
2017-03-23 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
SG11201700849XA
(en)
|
2014-08-07 |
2017-03-30 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
|
US10005760B2
(en)
|
2014-08-13 |
2018-06-26 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
|
ES2727952T3
(es)
*
|
2014-10-01 |
2019-10-21 |
Ratiopharm Gmbh |
Sal de adición de ácido de ibrutinib
|
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
|
US10485797B2
(en)
|
2014-12-18 |
2019-11-26 |
Principia Biopharma Inc. |
Treatment of pemphigus
|
|
EP3042903B1
(en)
|
2015-01-06 |
2019-08-14 |
Impetis Biosciences Ltd. |
Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
|
|
MA41350A
(fr)
*
|
2015-01-14 |
2017-11-21 |
Janssen Pharmaceutica Nv |
Synthèse d'un inhibiteur de la tyrosine kinase de bruton
|
|
US10266535B2
(en)
|
2015-01-21 |
2019-04-23 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Inhibitor of FLT3 kinase and use thereof
|
|
CN105481862B
(zh)
*
|
2015-01-21 |
2018-08-21 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
|
CN105859721B
(zh)
*
|
2015-01-22 |
2018-04-17 |
浙江京新药业股份有限公司 |
一种伊布鲁替尼的制备方法
|
|
US10214532B2
(en)
|
2015-02-12 |
2019-02-26 |
Shanghai Dude Medical Science and Technology Co., Ltd. |
Process for preparing ibrutinib
|
|
CN107613769A
(zh)
|
2015-02-17 |
2018-01-19 |
润新生物公司 |
某些化学实体、组合物和方法
|
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
|
|
US10045990B2
(en)
|
2015-03-04 |
2018-08-14 |
Arizona Board Of Regents On Behalf Of Arizona State University |
ERBB4 inhibitors and methods of use thereof
|
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
|
CN106146508A
(zh)
*
|
2015-03-19 |
2016-11-23 |
浙江导明医药科技有限公司 |
优化的联合用药及其治疗癌症和自身免疫疾病的用途
|
|
CN106146516B
(zh)
*
|
2015-04-20 |
2019-02-15 |
北京睿创康泰医药研究院有限公司 |
依鲁替尼药物杂质的制备方法
|
|
UA124090C2
(uk)
*
|
2015-06-03 |
2021-07-21 |
Прінсіпіа Байофарма Інк. |
Інгібітори тирозинкінази
|
|
US9394312B1
(en)
*
|
2015-06-14 |
2016-07-19 |
Mark Quang Nguyen |
Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use
|
|
TW201718572A
(zh)
|
2015-06-24 |
2017-06-01 |
普林斯匹亞生物製藥公司 |
酪胺酸激酶抑制劑
|
|
EA201890730A1
(ru)
|
2015-09-16 |
2018-10-31 |
Локсо Онколоджи, Инк. |
Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
|
|
WO2017103611A1
(en)
|
2015-12-16 |
2017-06-22 |
Redx Pharma Plc |
Compounds useful as kinase inhibitors
|
|
CN108473467B
(zh)
|
2015-12-24 |
2021-08-13 |
武田药品工业株式会社 |
共结晶、其制造方法及含有共结晶的药物
|
|
CA3009256C
(en)
*
|
2016-01-05 |
2023-08-22 |
Jiangsu Hengrui Medicine Co., Ltd. |
Crystalline form of btk kinase inhibitor and preparation method thereof
|
|
WO2017125423A1
(en)
*
|
2016-01-19 |
2017-07-27 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a btk inhibitor
|
|
US10662187B2
(en)
|
2016-01-21 |
2020-05-26 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
CN106995446B
(zh)
*
|
2016-01-22 |
2021-07-02 |
山东新时代药业有限公司 |
布鲁顿酪氨酸激酶抑制剂制备方法
|
|
KR102416971B1
(ko)
|
2016-03-11 |
2022-07-04 |
엔젤 파마슈티칼 컴퍼니, 리미티드 |
브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법
|
|
CN107383013B
(zh)
*
|
2016-05-16 |
2020-03-31 |
苏州信诺维医药科技有限公司 |
作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物
|
|
MA45547A
(fr)
|
2016-06-29 |
2019-05-08 |
Principia Biopharma Inc |
Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
|
|
US10864203B2
(en)
|
2016-07-05 |
2020-12-15 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
|
CN109843858B
(zh)
*
|
2016-08-15 |
2023-05-05 |
润新生物公司 |
某些化学实体、组合物及方法
|
|
CA3033827A1
(en)
|
2016-08-16 |
2018-02-22 |
Beigene, Ltd. |
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
|
|
PT3500299T
(pt)
|
2016-08-19 |
2024-02-21 |
Beigene Switzerland Gmbh |
Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
|
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
|
IL266239B2
(en)
|
2016-10-31 |
2023-10-01 |
Taiho Pharmaceutical Co Ltd |
A selective inhibitor of EGFR with an EXON 20 insertion mutation
|
|
JOP20190113A1
(ar)
*
|
2016-11-18 |
2019-05-15 |
Biocad Joint Stock Co |
مثبطات بروتون تيروزين كيناز
|
|
MA46995A
(fr)
|
2016-12-03 |
2019-10-09 |
Acerta Pharma Bv |
Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
WO2018145280A1
(zh)
*
|
2017-02-09 |
2018-08-16 |
合肥合源药业有限公司 |
Flt3激酶抑制剂或其盐的晶型及其制备方法
|
|
TW202515616A
(zh)
|
2017-06-26 |
2025-04-16 |
英屬開曼群島商百濟神州有限公司 |
抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
|
|
WO2019034009A1
(en)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
|
|
HUE066587T2
(hu)
|
2017-09-01 |
2024-08-28 |
Taiho Pharmaceutical Co Ltd |
Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor
|
|
TW201922256A
(zh)
|
2017-10-27 |
2019-06-16 |
中國大陸商浙江導明醫藥科技有限公司 |
治療淋巴樣惡性疾病之方法
|
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
|
CN108191871B
(zh)
*
|
2018-01-02 |
2020-02-18 |
成都倍特药业有限公司 |
新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
|
|
CN112533602A
(zh)
|
2018-04-05 |
2021-03-19 |
大日本住友制药肿瘤公司 |
Axl激酶抑制剂及其用途
|
|
CN117838695A
(zh)
|
2018-04-13 |
2024-04-09 |
住友制药肿瘤公司 |
用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
|
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
|
CN109134472B
(zh)
*
|
2018-09-20 |
2020-02-11 |
浙江理工大学 |
一种3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶-4-胺的合成工艺
|
|
CN110964016B
(zh)
*
|
2018-09-29 |
2021-05-28 |
南京药捷安康生物科技有限公司 |
氨基降茨烷衍生物及其制备方法与应用
|
|
CN109369654A
(zh)
*
|
2018-11-20 |
2019-02-22 |
山东大学 |
1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
|
|
WO2020131627A1
(en)
|
2018-12-19 |
2020-06-25 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药（上海）有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
TWI762939B
(zh)
|
2019-05-31 |
2022-05-01 |
大陸商海思科醫藥集團股份有限公司 |
Btk抑制劑環衍生物及其製備方法和藥學上的應用
|
|
WO2020249001A1
(zh)
|
2019-06-10 |
2020-12-17 |
百济神州瑞士有限责任公司 |
一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
|
|
CN110606848A
(zh)
*
|
2019-08-27 |
2019-12-24 |
药雅科技(上海)有限公司 |
一种5-氮杂吲哚衍生物Bruton′s酪氨酸激酶抑制剂及其制备方法与用途
|
|
TWI877239B
(zh)
|
2019-10-14 |
2025-03-21 |
美商普林斯匹亞生物製藥公司 |
藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
|
|
ES3033669T3
(en)
|
2019-11-08 |
2025-08-06 |
Nerviano Medical Sciences Srl |
Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
|
|
EP4093397A1
(en)
|
2020-01-20 |
2022-11-30 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
|
|
JP2023511105A
(ja)
|
2020-01-22 |
2023-03-16 |
プリンシピア バイオファーマ インコーポレイテッド |
２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態
|
|
CN113943294A
(zh)
*
|
2020-07-15 |
2022-01-18 |
成都海博为药业有限公司 |
一种作为btk抑制剂的化合物及其制备方法与用途
|
|
TW202221002A
(zh)
*
|
2020-11-25 |
2022-06-01 |
大陸商四川海思科製藥有限公司 |
一種btk降解劑的製備方法
|
|
AU2021398051A1
(en)
|
2020-12-10 |
2023-07-27 |
Principia Biopharma Inc. |
Crystal form of tolebrutinib, preparation method therefor and use thereof
|
|
CN113004246B
(zh)
*
|
2021-02-22 |
2022-02-01 |
广西医科大学 |
1，3，5-三嗪-2-胺-4，6取代衍生物或其药学上可接受的盐和用途
|
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
|
EP4611753A1
(en)
|
2022-10-31 |
2025-09-10 |
Sumitomo Pharma America, Inc. |
Pim1 inhibitor for treating myeloproliferative neoplasms
|